Melatonin Sublingual Tablet via Solubilizing Agent
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oral melatonin formulations suffer from poor and erratic bioavailability due to low water solubility, leading to delayed and inconsistent absorption, making them unsuitable for rapid onset of action and effective administration.
Innovation Solution
A pharmaceutical composition for sublingual or buccal administration of melatonin, where the hormone is dissolved in a pharmaceutically acceptable solvent and absorbed onto a carrier, forming a solid dosage form that maintains the hormone in a solubilized state, allowing direct absorption through the oral mucosa without gastrointestinal involvement.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If melatonin is administered orally in conventional preparations, then the dosage form is simple and easy to manufacture, but the bioavailability is poor and erratic with delayed onset of action
Solution Approach 1:
The patent uses a water-solubilizing agent as an intermediary substance to bridge the incompatibility between melatonin's lipophilic nature and the aqueous environment of the buccal cavity. The solubilizing agent forms a micellar or molecular dispersion that allows melatonin to be delivered in a water-based formulation, enabling rapid dissolution and absorption through the buccal mucosa without requiring complex lipid-based delivery systems.
Solution Approach 2:
The patent changes the physical-chemical parameters of the formulation by adjusting the concentration and type of water-solubilizing agent, pH, and other formulation parameters to optimize melatonin's solubility and stability in the aqueous buccal environment. This allows the hormone to maintain its therapeutic activity while achieving rapid dissolution and consistent bioavailability.
2Speed
If melatonin is formulated with water-solubilizing agents, then the dissolution rate and bioavailability are improved, but the formulation complexity increases
Solution Approach 1:
The patent employs commonly available, inexpensive water-solubilizing agents such as polysorbates, polyethylene glycols, or hydroxypropyl beta-cyclodextrin that are already widely used in pharmaceutical formulations. These agents provide effective solubilization without requiring complex or proprietary delivery systems, achieving rapid dissolution through simple, well-understood formulation approaches.
3Reliability
If high doses of melatonin are administered to overcome poor absorption, then the therapeutic effect may be achieved, but side effects increase
Solution Approach 1:
The water-solubilizing agent acts as a mediator that enhances the efficiency of melatonin delivery, allowing much smaller doses (e.g., 0.3-2.0 mg) to achieve therapeutic plasma concentrations. By improving the dissolution rate and bioavailability through the solubilizing agent, the formulation enables effective therapy at low doses, avoiding the side effects associated with high-dose administration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances bioavailability and achieves rapid onset of action with consistent melatonin plasma levels, similar to intravenous delivery, reducing the need for high doses and minimizing side effects associated with gastrointestinal absorption.
Implementation Method 1
the hormone is dissolved in a pharmaceutically acceptable solvent and absorbed onto a carrier, forming a solid dosage form that maintains the hormone in a solubilized state
Implementation Method 2
the hormone is dissolved in a pharmaceutically acceptable solvent and absorbed onto a carrier
Data Source
AI summary
The present invention provides a pharmaceutical composition for sublingual or buccal administration of actives with low to poor aqueous solubility, e.g. the indole hormone melatonin, which contains a solution of the active in a pharmaceutically acceptable solvent adsorbed or absorbed onto particles of a pharmaceutically acceptable carrier and methods of preparing and using the pharmaceutical composition.